Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck

Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.